Synaffix/Lonza End-to-End Offering to Best-in-Class Targeted-Therapies Based on GlycoConnect® & HydraSpace® Technologies
Time: 10:00 am
day: Conference Day Two pt 1
Details:
• Exploring how GlycoConnect® and HydraSpace® technologies enable ADCs with best-in-class therapeutic potential
• Sharing clinical development insights on the rapidly advancing pipeline of GlycoConnect® ADCs by partners
• Discussing technology expansion towards bispecific (bYlok®) and dual warhead ADCs with compelling in vivo data
• Presenting unprecedented mRNA exon skipping and dystrophin restoration in preclinical mouse model for Duchenne muscular dystrophy
